Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor A Levin

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Journal of Neuro-Oncology|October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium studyVinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology|September 26, 2015
CNS Anticancer Drug Discovery and Development Conference White PaperVictor A Levin, Peter J Tonge, James M Gallo, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Neuro-Oncology|March 4, 2008
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiformeVinay K Puduvalli, Pierre Giglio, Morris D Groves, et al.
Journal of Neuro-Oncology|October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Neuro-Oncology|October 27, 2012
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02Eudocia Q Lee, John Kuhn, Kathleen R Lamborn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2004
Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium studyVinay K Puduvalli, W K Alfred Yung, Kenneth R Hess, et al.
Neuro-Oncology Advances|November 25, 2020
Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02Huanwen Chen, John Kuhn, Kathleen R Lamborn, et al.
Neuro-Oncology|September 26, 2015
CNS Anticancer Drug Discovery and Development Conference White PaperVictor A Levin, Peter J Tonge, James M Gallo, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 AstrocytomaHoward Colman, Giuseppe Lombardi, Eric T Wong, et al.
Pageof 6